ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

09/12/2026, 9:54 AM • GlobeNewswire

רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY

Rosen Law Firm is urging investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) who purchased securities between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The lawsuit alleges that company defendants made false and misleading statements regarding the expected timeline for CVS Caremark insurance coverage expansion for the company's epinephrine spray product, neffy, causing investors to purchase shares at artificially inflated prices. The deadline to file is October 5, 2026.

09/09/2026, 9:50 PM • GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

Rosen Law Firm is encouraging investors who purchased securities of ARS Pharmaceuticals (SPRY) between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The firm alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

09/09/2026, 5:32 PM • GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

Rosen Law Firm is notifying investors of ARS Pharmaceuticals (SPRY) about a securities class action lawsuit with an October 5, 2026 lead plaintiff deadline. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray 'neffy' through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

09/06/2026, 2:16 PM • GlobeNewswire

WSE DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Wise Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – WSE

Rosen Law Firm has filed securities class actions against multiple companies, including Wise Group plc (WSE), alleging false and misleading statements regarding regulatory compliance and anti-money laundering efforts. Investors with losses exceeding $100K are encouraged to join the class action before the September 29, 2026 deadline.

09/03/2026, 8:21 PM • GlobeNewswire

ROSEN, A TOP-RANKED LAW FIRM, Encourages Park Ha Biological Technology Co., Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - PHH, BYAH

Rosen Law Firm is seeking lead plaintiffs for securities class action lawsuits against Park Ha Biological Technology Co., Ltd. and other companies. The firm alleges that Park Ha made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, artificially low public float, and manipulated trading activity during the class period of December 27, 2024 to July 8, 2025. The lead plaintiff deadline is September 28, 2026.

08/31/2026, 10:01 PM • GlobeNewswire

ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.

08/31/2026, 9:56 PM • GlobeNewswire

CAR DEADLINE: ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Against Pentwater Capital Management LP - CAR

Rosen Law Firm is notifying investors in Avis Budget Group, ARS Pharmaceuticals, and Bloom Energy Corporation of ongoing securities class action lawsuits. The primary case involves allegations that Pentwater Capital Management LP and its CEO manipulated Avis stock prices through aggressive purchasing that triggered a short squeeze, benefiting Pentwater's substantial holdings. Investors with losses exceeding $100K are encouraged to join the class actions before the September 29, 2026 deadline.

08/31/2026, 9:32 PM • GlobeNewswire

ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding insurance coverage timelines for its epinephrine nasal spray product 'neffy' with CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

08/28/2026, 5:50 PM • GlobeNewswire

ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against ARS Pharmaceuticals (NYSE:SPRY) for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product 'neffy' with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to disclose risks of delays that would impact summer and back-to-school seasons. Investors who purchased ARS securities between March 9 and June 24, 2026 can apply to be lead plaintiff by October 5, 2026.

08/27/2026, 3:54 PM • GlobeNewswire

ROSEN, NATIONAL TRIAL COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY

Rosen Law Firm is reminding investors who purchased ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026 of an October 5, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

08/25/2026, 7:40 PM • GlobeNewswire

EQPT DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages EquipmentShare.com Inc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - EQPT

Rosen Law Firm is notifying investors in EquipmentShare.com Inc, ARS Pharmaceuticals Inc, and Barclays PLC of ongoing securities class action lawsuits. EquipmentShare investors who purchased shares during the IPO or within the Class Period are encouraged to join the lawsuit, with a lead plaintiff deadline of September 21, 2026. The lawsuits allege material misstatements and omissions regarding business operations and financial disclosures.

08/25/2026, 7:34 PM • GlobeNewswire

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed ARS Pharmaceutic (SPRY)

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product neffy through CVS Caremark. The company failed to disclose risks that the July 1, 2026 coverage deadline might not be met. When the truth emerged on June 24, 2026, ARS stock declined over 23.9% in a single day.

08/06/2026, 3:46 PM • GlobeNewswire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of ARS Pharmaceuticals, Inc. Securities and Sets a Lead Plaintiff Deadline of October 5, 2026

Law firm Levi & Korsinsky has filed a class action lawsuit against ARS Pharmaceuticals for allegedly making false and misleading statements regarding expanded insurance coverage for its drug neffy through CVS Caremark. The company failed to meet its July 1, 2026 deadline for coverage expansion, causing the stock to plummet 23.9% on June 25, 2026. Investors who purchased securities between March 9 and June 24, 2026 can join the lawsuit with a lead plaintiff deadline of October 5, 2026.

08/05/2026, 5:43 PM • GlobeNewswire

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, with neffy (epinephrine nasal spray) generating $17.5 million in U.S. net product revenue. The company expanded its sales force to 148 representatives, secured approval from Health Canada, and achieved European Commission marketing authorization for EURneffy 1 mg. CVS Caremark formulary approval is in final stages with expected July 2026 effective date. The Phase 2b CSU trial interim population is fully enrolled with Q4 2026 readout expected. Despite strong commercial momentum, the company reported a net loss of $60.6 million for the quarter.

05/15/2026, 6:00 AM • GlobeNewswire